$LLY Trade Levels (Weekly)Entry Zone (Demand): $680 – $700
Stop-Loss: Below $660 (invalidates demand zone)
First Target (Resistance): $800 – $820
Second Target (Supply): $880 – $920
R/R Setup: ~1:3 if entry at demand and target at upper supply
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
10 CHF
9.62 B CHF
40.91 B CHF
848.59 M
About Eli Lilly and Company
Sector
Industry
CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
ISIN
US5324571083
FIGI
BBG00Z4HJVR2
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Related stocks
Eli Lilly (LLY) Weekly Chart – Double Top Patterns & Major SuppoLLY has formed consecutive double top patterns within a broad descending channel.
Price recently tested a long-term major support zone and bounced strongly, signaling renewed buying interest. If this momentum holds, a move toward the major resistance near $973 is possible, aligning with the upper
$LLY: Decision Zone — Wedge Breakout or Retest of 685Eli Lilly (LLY) rebounded off the long-term trendline and weekly demand box (≈622–686) and is compressing inside a descending wedge.
Bullish path (blue): a clean break and retest of wedge resistance opens room toward the prior extension/marker near ~970.
Bearish path (red): rejection at the
Lilly Has Fallen. Can it Get Up?Eli Lilly has been trending lower, and some traders may see further downside risk in the pharma giant.
The first pattern on today’s chart is the bearish gap on August 7. The decline came despite better-than-expected quarterly results, which may reflect weakening fundamentals.
Second is the May 23
Still in Mark-Down stageBelow the 200 DMA and the VWAP anchored to the stage 2 mark-up start. I don't think we're at the accumulation stage yet. Not even close.
LLY - Clean Levels UpdatedEli Lilly's hit those 708.49 and 711 levels I mentioned in my previous LLY post.
I've added some weekly levels, and a couple relevant spots from my boxed LLY chart.
If LLY loses steam up here we could easily see a retest of that box top area in the $680 - $678 range. Otherwise if we see a market
LLY eyes on $635.82: Major fib may hold earnings + news CRASHLLY earnings plus some GLP news tanked the stock.
But the crash came to an abrupt halt at a Genesis fib.
Look for a bounce but expect bears at the Golden's above.
LLY $720 Call Setup: Don’t Miss Out on This Breakout Play!🚀 LLY Weekly Options Analysis (2025-08-17) 🚀
### 🔎 Comprehensive Multi-Model Insights
**Grok/xAI Report**
* 📊 RSI: Neutral (Daily & Weekly \~46)
* 📈 Flow: Call/Put = **3.87 (Bullish bias)**
* 🔊 Volume: Weak vs. previous weeks → ⚠️ no strong institutional support
* 🛑 Trade: **No entry** (weak conf
LLY AUG-2025Eli Lilly ( NYSE:LLY ) rebounded strongly from the 640 support zone after institutional absorption. Price is now targeting the gap at 740, aligning with prior distribution levels. Sustained momentum above 700 could drive continuation into 737–740. Failure to hold above 640 risks a deeper move into t
Red Pill or Blue Pill?Red Pill first - let’s stick to some harsh realities, but using technical analysis only.
Why the harsh crash?
We were rejected at the Value Area high at $972, followed by another rejection at the 0.786 Fibonacci level at $916, along with the top of the flag pattern of this giant bull flag. This wa
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
LLY6003481
Eli Lilly and Company 4.75% 12-FEB-2030Yield to maturity
—
Maturity date
Feb 12, 2030
LLY6003480
Eli Lilly and Company 4.55% 12-FEB-2028Yield to maturity
—
Maturity date
Feb 12, 2028
LLY6003092
Eli Lilly and Company 5.1% 12-FEB-2035Yield to maturity
—
Maturity date
Feb 12, 2035
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044Yield to maturity
—
Maturity date
Jun 15, 2044
LLY5871803
Eli Lilly and Company 5.05% 14-AUG-2054Yield to maturity
—
Maturity date
Aug 14, 2054
LLY6153504
Eli Lilly and Company 4.55% 15-OCT-2032Yield to maturity
—
Maturity date
Oct 15, 2032
LLY6003397
Eli Lilly and Company 5.6% 12-FEB-2065Yield to maturity
—
Maturity date
Feb 12, 2065
LLY.HW
Eli Lilly and Company 5.95% 15-NOV-2037Yield to maturity
—
Maturity date
Nov 15, 2037
LLY5871809
Eli Lilly and Company 4.15% 14-AUG-2027Yield to maturity
—
Maturity date
Aug 14, 2027
LLY5547404
Eli Lilly and Company 4.875% 27-FEB-2053Yield to maturity
—
Maturity date
Feb 27, 2053
LLY5546986
Eli Lilly and Company 4.7% 27-FEB-2033Yield to maturity
—
Maturity date
Feb 27, 2033
See all LLYZ bonds
Curated watchlists where LLYZ is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on TURQUOISE exchange Eli Lilly and Company stocks are traded under the ticker LLYZ.
We've gathered analysts' opinions on Eli Lilly and Company future price: according to them, LLYZ price has a max estimate of 955.06 CHF and a min estimate of 561.80 CHF. Watch LLYZ chart and read a more detailed Eli Lilly and Company stock forecast: see what analysts think of Eli Lilly and Company and suggest that you do with its stocks.
LLYZ reached its all-time high on Mar 1, 2024 with the price of 705 CHF, and its all-time low was 200 CHF and was reached on Jun 7, 2021. View more price dynamics on LLYZ chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track Eli Lilly and Company financials in yearly and quarterly reports right on TradingView.
Eli Lilly and Company is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
LLYZ earnings for the last quarter are 5.01 CHF per share, whereas the estimation was 4.44 CHF resulting in a 12.70% surprise. The estimated earnings for the next quarter are 5.07 CHF per share. See more details about Eli Lilly and Company earnings.
Eli Lilly and Company revenue for the last quarter amounts to 12.34 B CHF, despite the estimated figure of 11.67 B CHF. In the next quarter, revenue is expected to reach 12.78 B CHF.
LLYZ net income for the last quarter is 4.49 B CHF, while the quarter before that showed 2.44 B CHF of net income which accounts for 83.86% change. Track more Eli Lilly and Company financial stats to get the full picture.
Yes, LLYZ dividends are paid quarterly. The last dividend per share was 1.21 CHF. As of today, Dividend Yield (TTM)% is 0.77%. Tracking Eli Lilly and Company dividends might help you take more informed decisions.
Eli Lilly and Company dividend yield was 0.67% in 2024, and payout ratio reached 44.39%. The year before the numbers were 0.78% and 77.91% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 15, 2025, the company has 47 K employees. See our rating of the largest employees — is Eli Lilly and Company on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Eli Lilly and Company EBITDA is 19.30 B CHF, and current EBITDA margin is 41.75%. See more stats in Eli Lilly and Company financial statements.
Like other stocks, LLYZ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eli Lilly and Company stock right from TradingView charts — choose your broker and connect to your account.